Biotech companies raise capital on clinical promise but grow on commercial execution. The ones that scale build growth infrastructure alongside their pipeline — not after approval forces them to scramble.

The Problem

Growth planning starts at the wrong milestone

Most biotech companies treat growth strategy as a post-approval concern. But the decisions that determine growth trajectory — market positioning, pricing strategy, channel design, team structure — need 18-24 months of development. Companies that wait for Phase III results to start growth planning launch into markets they haven't prepared, with teams they haven't built, using strategies they haven't tested.

Scientific founders struggle with commercial growth decisions

Your founding team built breakthrough science. But growth strategy requires different pattern recognition — understanding payer economics, physician adoption curves, specialty pharmacy distribution, and competitive market dynamics. Without commercial growth expertise on the leadership team, decisions get made based on clinical logic rather than market logic, and they compound into structural growth limitations.

Single-product growth ceiling limits company valuation

Investors value biotech companies on platform potential, not single-product revenue. But most growth strategies focus exclusively on the lead asset. Companies that build growth strategy across their portfolio — including lifecycle management, indication expansion, and platform development — create the multi-product narrative that commands premium valuations and attracts strategic partnership interest.

How We Help

Our initial assessment maps your growth potential across three horizons: lead asset commercialization, pipeline expansion, and platform value creation. Most biotech companies over-index on the first horizon and under-invest in the narrative and infrastructure for horizons two and three — which is exactly what investors and partners are evaluating.

Strategy development builds an integrated growth plan that connects clinical milestones to commercial outcomes. For your lead asset, we develop go-to-market strategy, market access planning, and launch sequencing. For your pipeline, we create growth models that connect clinical development decisions to commercial potential. For your platform, we build the strategic narrative that positions your company for premium valuation and partnership interest.

Execution focuses on building the growth infrastructure your company needs at its current stage. Early-stage companies need investor positioning and commercial narrative development. Mid-stage companies need market access groundwork and commercial team building. Late-stage companies need full launch readiness and growth optimization. We scale our engagement to match your pipeline maturity and capital position.

Measurement tracks growth readiness against your development timeline. We establish commercial milestones for each asset and horizon, monitor competitive developments, and adjust growth strategy as market conditions evolve. Board-ready reporting connects growth progress to company valuation and fundraising narratives.

What we deliver

Multi-horizon growth strategy — lead asset, pipeline, and platform growth plans
Commercial growth model — financial projections connecting clinical milestones to revenue potential
Investor narrative — growth story that connects clinical promise to commercial value creation
Growth infrastructure roadmap — team, tools, and capabilities needed at each stage

Biotech investors don't fund science — they fund commercial potential. The companies that raise at premium valuations are the ones that can articulate exactly how clinical milestones become revenue, and they start building that story years before it becomes true.

Our Methodology

Our growth strategy methodology for biotech starts with total addressable market validation, not assumptions from investor decks. Phase one pressure-tests your market sizing, competitive positioning, and revenue assumptions against real payer, prescriber, and patient data. Most companies discover their growth projections need significant refinement based on actual market access dynamics.

Phase two builds the strategic framework across all growth horizons. Lead asset strategy gets the deepest treatment — pricing, market access, launch sequencing, and commercial team design. Pipeline and platform strategies receive framework-level planning that connects to investor narratives. We develop the financial models that translate clinical probability-adjusted timelines into revenue scenarios.

Phase three implements priority growth initiatives and establishes the reporting cadence. Quarterly growth reviews assess progress against milestones, competitive landscape changes, and market access developments. The output is a living growth strategy that evolves with your pipeline — not a static document that's outdated by the next board meeting.

How We Work

Growth strategy engagements for biotech typically run 6-18 months depending on pipeline complexity and development stage. The first 45 days focus on comprehensive market analysis, competitive assessment, and growth model development. We interview stakeholders across your organization, analyze payer and prescriber landscapes, and build financial models that connect clinical timelines to commercial outcomes.

Months 2-4 develop the strategic framework and begin infrastructure building. Growth strategies get pressure-tested with investor-quality financial modeling. Priority initiatives are launched — whether that's market access groundwork, commercial team design, or investor narrative development.

Months 4+ are ongoing strategy execution and optimization. Quarterly growth reviews keep strategy aligned with pipeline developments and market changes. We adjust growth models as clinical data matures and competitive dynamics shift.

Your growth strategy engagement includes executive-level partnership — we attend board meetings, investor sessions, and strategic planning offsites as growth strategy advisors. Monthly reporting tracks commercial readiness milestones and growth infrastructure development.

Valuation impact — growth strategy that supports premium fundraising multiples
Launch preparedness — commercial infrastructure built on pipeline timelines
Portfolio narrative — multi-horizon growth story that attracts investors and partners

If your biotech & pharma company needs growth strategy leadership, we should talk.

Expand your marketing team output with our experts

Let us take a custom approach to your growth goals by assembling and leading the best-in-class marketing team to support your next stage.

Frequently asked questions

How much does growth strategy cost for biotech companies?

Growth strategy engagements typically range from $25K-$60K per month depending on pipeline complexity and scope. For companies approaching major clinical or fundraising milestones, the investment pays for itself through improved investor conversations and launch readiness. A well-articulated growth strategy directly impacts valuation — which at Series B or later translates to millions in fundraising efficiency.

How early should a biotech company invest in growth strategy?

Series A companies need growth narrative development that supports fundraising. Series B companies need commercial growth infrastructure planning. Pre-launch companies need full growth strategy execution. The earlier you build growth strategy, the more runway you have to make high-quality commercial decisions. Most companies wish they'd started 12 months earlier than they did.

How does growth strategy differ from go-to-market planning?

Go-to-market is one component of growth strategy focused on launch execution for a specific asset. Growth strategy is broader — encompassing multi-horizon portfolio planning, platform value creation, investor positioning, and the organizational capabilities needed to sustain growth across multiple products and indications. GTM answers 'how do we launch this product.' Growth strategy answers 'how do we build a growing company.'

What makes Winston Francois different from management consulting firms for biotech growth?

Management consulting firms produce thick strategy decks and leave. We build growth strategies and stay to help execute them. Our team combines strategic advisory with hands-on commercial building — meaning your growth strategy connects directly to the operational reality of building a commercial biotech company. We've seen what actually works in launch execution, not just what looks good in a slide deck.

How do you measure growth strategy effectiveness?

We track commercial readiness milestones, fundraising outcomes (valuation, investor quality, time to close), partnership interest quality, and post-launch commercial performance against projections. Growth strategy effectiveness ultimately shows up in two places: how well your fundraising rounds go and how well your products perform commercially. We establish benchmarks for both.

What type of biotech company needs growth strategy services?

Series A through commercial-stage companies with at least one clinical-stage asset. Ideal clients have strong science and clinical teams but lack the commercial growth expertise to translate pipeline potential into market leadership. If you're pre-clinical without a clear development path, growth strategy is premature — focus on scientific validation first. The first step is a growth readiness assessment.